“Would a medicine help?” is a fair question. So is “What would it help with?” A drug may reduce one eating-disorder symptom or help with a part of nutritional recovery. It may treat depression or attention-deficit/hyperactivity disorder, known as ADHD, that makes daily life harder. These are different goals. The plan should name which one you are trying to reach.
No medicine replaces the full assessment and care an eating disorder may need. Yet the lack of a cure in a pill does not mean a prescriber has nothing to offer. The evidence needs to fit your age, health, and goals. Your diagnosis matters too.1
Start with the target, not the drug name
A person may need care for both an eating disorder and another mental-health condition. Some symptoms can overlap. Trouble focusing, poor sleep, anxiety, and low mood may have several causes, including too little nutrition. The team may need time and follow-up to understand them. The order and timing of that care is a clinical judgment your team makes with you, not a fixed rule.1
Ask what change would count as a benefit. Is the goal less loss of control? Less depression? Being more able to take part in treatment? A change in one area does not prove that the rest of the illness has improved. Weight change alone is not a full measure of eating-disorder recovery.
The table can guide that talk. It is not a list of drugs to request or a dosing plan. BED stands for binge-eating disorder. OCD means obsessive-compulsive disorder. ARFID stands for avoidant/restrictive food intake disorder. FDA means the U.S. Food and Drug Administration, which approves drugs for specific uses.
| Condition | What to know |
|---|---|
| Adult bulimia nervosa | What a medicine may help: Fluoxetine can reduce binge and vomiting symptoms. What it cannot replace: Eating-disorder therapy, nutrition support, and medical care. Key limitation to discuss: Partial response is common; other ages and uses have different evidence. |
| Moderate to severe BED in adults | What a medicine may help: Lisdexamfetamine can reduce binge symptoms. What it cannot replace: Care for distress, eating patterns, and broader health. Key limitation to discuss: Selected adult trials; appetite, heart, psychiatric, and misuse risks matter. |
| Adult anorexia nervosa | What a medicine may help: Off-label olanzapine may support modest weight gain in some patients. What it cannot replace: Nutritional rehabilitation and psychological treatment. Key limitation to discuss: A weight benefit does not establish broad psychological recovery. |
| Depression, anxiety, OCD, or ADHD alongside an eating disorder | What a medicine may help: A suitable medicine may address the separate condition. What it cannot replace: Eating-disorder assessment and coordinated treatment. Key limitation to discuss: Nutrition, medical status, age, and interactions change the decision. |
| ARFID | What a medicine may help: Medicines may sometimes address another condition or symptom. What it cannot replace: A plan for the reasons eating is restricted. Key limitation to discuss: No FDA-approved medication specifically treats ARFID. |
These points come from current U.S. labels, guidelines, and studies of each diagnosis. Approval for one condition should not be carried over to another.12345
Anorexia: no approved drug is not the same as no possible benefit
There is no FDA-approved drug specifically for anorexia nervosa. That describes its approval status. It does not prove that every drug has no benefit for every outcome. Restoring nutrition and therapy focused on the eating disorder remain central to treatment.15
One studied option is olanzapine, used off-label for anorexia. Off-label means the FDA has not approved that use. One trial randomly assigned adults in outpatient care to this drug or a placebo with no active drug. Those taking olanzapine gained weight somewhat faster. The trial found no significant benefit on its main measure of obsessional symptoms. Almost all who took part were women, and the study lasted only a few months.4
A later review that pooled study results also found a modest weight benefit in adults. The evidence in teens remained uncertain. We cannot assume the same benefit for children or people in hospital whose medical state is unstable. It also cannot be assumed for everyone with restrictive eating. Nor do the findings show that olanzapine resolves fear, body distress, or all anorexia symptoms.6
Olanzapine can cause sleepiness, dizziness when standing, and changes in blood sugar and fats called lipids. Those risks still matter when a person needs to restore nutrition. Follow-up checks should reflect the person’s health needs and the label for the drug taken by mouth. Some lab results did not differ between groups in the short trial. That does not rule out longer-term harm.47
A talk about off-label treatment should cover what benefit is possible and what remains uncertain. Ask how you and the prescriber will judge whether it helps. You can ask for that explanation in plain language before giving consent.
Fluoxetine has a defined role in adult bulimia
Fluoxetine has a U.S. approval for binge-eating and vomiting behaviors in patients with moderate to severe bulimia. The trials behind it enrolled adults, and the label gives a dose only for adults. In studies supporting that use, it reduced symptoms more than placebo on average. Many patients still had symptoms. The prescriber should be clear about the benefit you might expect.2
The Prozac label’s studied and recommended bulimia dose is 60 mg daily, managed by a prescriber. This is not a starting instruction or a target for changing your own dose. The label states that doses above 60 mg a day have not been systematically studied for bulimia. A dose limit for depression or OCD does not establish an evidence-based bulimia limit.2
For adult bulimia, the American Psychiatric Association recommends cognitive behavioral therapy, or CBT, focused on the eating disorder. It also recommends a serotonin reuptake inhibitor, a type of antidepressant, either from the start or if therapy alone has not helped much after about six weeks. Medicine still cannot replace a medical assessment, nutrition, or therapy. The bulimia essay explains why health risks may arise before others notice symptoms.1
Lisdexamfetamine treats adult BED, not a number on a scale
Lisdexamfetamine has a U.S. approval for moderate to severe BED in adults. Its ADHD approval includes younger patients. That does not extend the BED approval to children. The label is direct about this: the medicine is not indicated or recommended for weight loss, and the label warns that similar stimulant-type drugs used for weight loss have caused serious heart problems. The label also says its safety and effect in treating obesity have not been established.3
Short-term trials found a reduction in binge-eating days. A longer study first selected people who had responded to the drug. Among them, those who kept taking it had less relapse than those switched to placebo. This tells us about keeping an initial benefit. It does not tell us the chance of benefit for every person starting care.38
A newer trial studied selected adults with BED and obesity. More reached short-term binge remission with CBT and lisdexamfetamine together than with either alone. This adds evidence for one combined approach. It does not settle long-term treatment choices. It also does not justify ranking drugs and therapies from separate, unrelated trials.9
Lisdexamfetamine can help one symptom while causing problems elsewhere. Less appetite, trouble sleeping, or a faster heart rate need review. Its boxed warning covers abuse, misuse, and addiction. Prescribers also assess heart and mental-health risks. Tell yours about trouble eating enough or new mood and sleep changes. Do not decide on a dose change yourself.3
The adult BED essay covers therapy and how to ask for help in more depth. The GLP-1 essay explains why less appetite is not the same outcome as eating-disorder recovery.
What about antidepressants during malnutrition?
Being undernourished can also change how safe a medicine is, not just how well it works. Low body salts, a slow heart rate, and heart-rhythm changes are common in restrictive eating disorders, and some medicines add to that risk, so this belongs in the same conversation.
It is too simple to say that antidepressants cannot work in an undernourished brain. Studies of anorexia have asked narrower questions. A small fluoxetine trial in hospital patients found no added benefit on its measured outcomes. This does not prove a rule about how all brains work. It also does not show that depression alongside an eating disorder can never benefit from care.10
A larger trial took place after weight restoration. Both groups had CBT. Overall, fluoxetine did not do better at preventing relapse. In 2025, researchers looked again at the same data. They found a possible benefit in a small group with more persistent depression. This was an exploratory analysis, so further research needs to test the finding. It should not overturn the overall result or become a rule for prescribing.1112
Your clinician may ask about symptoms before food restriction began and how they change with nutrition. Past responses to treatment and current medical risks also matter. Depression, OCD, anxiety, and ADHD are different problems. There should be a clear reason to treat each one while eating-disorder care continues.
This is also why a chemical-imbalance explanation is not enough. You deserve clear goals that you and your team can assess, along with a review of risks. That remains true even when the cause of a symptom is uncertain.
Safety questions that belong in the room
Bupropion’s U.S. label lists a current or past diagnosis of anorexia nervosa or bulimia nervosa as a contraindication. This means a reason not to use it, in this case due to seizure risk. Do not extend that exact label rule to every eating disorder. If this history applies to you and you take bupropion, contact the prescriber to review it. Do not stop it on your own or skip doses while you wait. Some medicines cause withdrawal effects or a return of symptoms when they are stopped suddenly, so any change should be planned with your prescriber. This article does not tell you to stop or change treatment.13
Other safety issues depend on the drug and the person. Problems with fluids or electrolytes, which are body salts, can affect heart risk and interact with some drugs. Antidepressants carry warnings about suicidal thoughts in younger people. Stimulants can affect appetite and growth in children. Each risk needs review. So do questions about pregnancy or breastfeeding. A blanket safe-drug list cannot replace that review.123
An electrocardiogram, or ECG, records the heart’s electrical activity. In its 2023 guideline, the American Psychiatric Association recommends an ECG at the initial assessment for specific groups. These include people with restrictive eating disorders or severe purging. They also include people taking drugs known to lengthen a heart-rhythm interval called QTc. The advice applies to those groups. It is not a repeated ECG schedule for everyone taking mental-health medicines.1
Follow-up tests depend on findings, symptoms, medical risk, and the drug’s label. Who will order them? Who will review the results? Even if a test was normal once, you still need to report new symptoms.
Bring three questions this week
You can open the visit with: “What is this medicine meant to help, and how will we know? I also want to understand how we will monitor it alongside my eating-disorder care.”
Bring these questions:
What specific symptom or condition are we treating?
What evidence of benefit should we look for, beyond appetite or weight change?
Which side effects and follow-up checks matter for me, and whom do I contact between visits?
This week, make a current medicine and supplement list and request that discussion. Include past eating diagnoses, current eating concerns, and any pregnancy or breastfeeding questions. If you need more support to manage the risks, the levels-of-care essay can help you ask for it.
Seek emergency medical care for collapse, chest pain, a seizure, a heartbeat that feels fast, pounding, or irregular, severe confusion, or vomiting blood. Severe dehydration, including being unable to keep fluids down, also needs emergency care. In the United States, call 911 for an emergency or immediate danger. Call or text 988 for a suicidal or mental-health crisis. 988 does not replace emergency medical care.1415
This article is for education and does not replace care from your own health professional. Eating disorders can affect people at any body size. If you are concerned about eating, exercise, or related symptoms, ask for an assessment. Do not start, stop, or change medication based on this article.
This article is for education only. It does not recommend, start, stop, or change any medication, does not state a dose for you, and does not replace a prescriber’s judgment. It does not diagnose an eating disorder or set a target weight. Off-label use is identified where it appears. Drug labeling changes; the labels cited here were current on September 7, 2026. Reading it does not create a clinician-patient relationship.
Eating disorder support and referrals
These are specialized eating disorder helplines, not 24/7 crisis lines. For urgent help any time, use the crisis resources below.
- National Alliance for Eating Disorders Helpline, 1-866-662-1235, Monday to Friday, 6 a.m. to 4 p.m. Pacific (9 a.m. to 7 p.m. Eastern). Staffed by licensed therapists who specialize in eating disorders; free referrals to all levels of care. allianceforeatingdisorders.com
- ANAD Helpline, 1-888-375-7767, Monday to Friday, 7 a.m. to 7 p.m. Pacific (9 a.m. to 9 p.m. Central). Peer support and treatment referrals.
- F.E.A.S.T., feast-ed.org. Free caregiver resources, online support groups, and family guides for those supporting a loved one with an eating disorder.
If you or your loved one has chest pain, fainting, seizures, severe weakness, confusion, signs of refeeding syndrome, or any other life-threatening symptom, call 911 or go to the nearest emergency room. Eating disorders are medical illnesses, and medical emergencies are common.
Related reading on NP FADY
- Binge Eating Is Not a Willpower Problem
- What Bulimia Costs Before Anyone Notices
- Nobody Ages Out of an Eating Disorder
References
1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Eating Disorders, 4th ed. 2023. DOI: 10.1176/appi.books.9780890424865. Summary: Am J Psychiatry. 2023;180(2):167-171. Statements quoted from the Guideline Central pocket guide summarizing that guideline. Statements 8, 13, 15, 16; hosted by Alliance Health. https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines/eating-disorders. Pocket-guide copy: https://www.alliancehealthplan.org/document-library/83757/. Accessed September 7, 2026.
2. PROZAC prescribing information. U.S. label revised August 2023; current record checked September 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c88f33ed-6dfb-4c5e-bc01-d8e36dd97299. Accessed September 7, 2026.
3. VYVANSE prescribing information. U.S. label revised April 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad. Accessed September 7, 2026.
4. Attia E et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa. 2019. DOI: 10.1176/appi.ajp.2018.18101125. https://pubmed.ncbi.nlm.nih.gov/30654643/. Accessed September 7, 2026.
5. NIMH. Eating Disorders: What You Need to Know. https://www.nimh.nih.gov/health/publications/eating-disorders. Accessed September 7, 2026.
6. Han R et al. Effectiveness of olanzapine in the treatment of anorexia nervosa: systematic review and meta-analysis. 2022. DOI: 10.1002/brb3.2498. https://pmc.ncbi.nlm.nih.gov/articles/PMC8865148/. Accessed September 7, 2026.
7. ZYPREXA (olanzapine) tablets, orally disintegrating tablets, and intramuscular injection prescribing information. U.S. label revised January 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b418946a-1ab4-4d89-a012-d94fc361a3c4. Accessed September 7, 2026.
8. Hudson JI et al. Lisdexamfetamine randomized withdrawal study in adults with BED. 2017. DOI: 10.1001/jamapsychiatry.2017.1889. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2642925. Accessed September 7, 2026.
9. Grilo CM et al. CBT and lisdexamfetamine, alone and combined, for BED with obesity. 2025; online 2024. DOI: 10.1176/appi.ajp.20230982. https://pubmed.ncbi.nlm.nih.gov/39659158/. Accessed September 7, 2026.
10. Attia E et al. Does fluoxetine augment the inpatient treatment of anorexia nervosa? 1998. DOI: 10.1176/ajp.155.4.548. https://pubmed.ncbi.nlm.nih.gov/9546003/. Accessed September 7, 2026.
11. Walsh BT et al. Fluoxetine after weight restoration in anorexia nervosa. 2006. DOI: 10.1001/jama.295.22.2605. https://pubmed.ncbi.nlm.nih.gov/16772623/. Accessed September 7, 2026.
12. Lloyd EC et al. Fluoxetine after weight restoration: moderation of effect by depression. 2025. DOI: 10.1017/S003329172510127X. https://www.cambridge.org/core/services/aop-cambridge-core/content/view/BD0F4C25348D176284C6AD6E4E0C2ACA/S003329172510127Xa.pdf/fluoxetine-for-anorexia-nervosa-after-weight-restoration-moderation-of-effect-by-depression.pdf. Accessed September 7, 2026.
13. WELLBUTRIN XL prescribing information. U.S. label revised November 2025; current record checked September 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a435da9d-f6e8-4ddc-897d-8cd2bf777b21. Accessed September 7, 2026.
14. Royal College of Psychiatrists. MEED, CR233. 2022; updated December 2025. https://www.rcpsych.ac.uk/improving-care/campaigning-for-better-mental-health-policy/college-reports/2022-college-reports/cr233. Accessed September 7, 2026.
15. 988 Suicide & Crisis Lifeline. Current U.S. service information. https://988lifeline.org/. Accessed September 7, 2026.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.